Simplify Logo

Internship

Regulatory Co-Op

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

201-500 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Cambridge, MA, USA

Hybrid working environment.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Communications
Requirements
  • Pursuing a bachelor’s degree in a medical or scientific field.
  • Demonstrated ability to analyze and present strategy, either through coursework or leadership position in a student or civic organization.
  • A team player who is curious, motivated to learn, organized, and has excellent communication skills.
Responsibilities
  • Assist the regulatory strategy leads in setting, supporting, and executing regulatory activities.
  • Support improvement and implementation of regulatory processes including chronology logs, trackers, and research regulatory precedent and competitive intelligence.
  • Participate in cross-functional meetings and discussions as appropriate.
  • Learn about and support other regulatory functions including CMC, Operations, and Labeling.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and advance their projects. Their goal is to advance scientific research and deliver effective, long-lasting treatments for patients.

Company Stage

IPO

Total Funding

$689M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

4%

1 year growth

-8%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.